Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 30, 2018	May 01, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	INTEGER HOLDINGS CORPORATION
Entity Central Index Key	0001114483
Document Type	10-Q
Document Period End Date	Mar. 30, 2018
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-28
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		32,013,674

Condensed Consolidated Balance Sheets - Unaudited - USD ($) $ in Thousands	Mar. 30, 2018	Dec. 29, 2017
Current assets:
Cash and cash equivalents	$ 29,488	$ 44,096
Accounts receivable, net of allowance for doubtful accounts of $0.7 million and $0.8 million, respectively	242,218	242,456
Inventories	239,490	227,534
Refundable income taxes	494	37
Prepaid expenses and other current assets	17,071	17,786
Total current assets	528,761	531,909
Property, plant and equipment, net	367,664	370,375
Goodwill	995,200	990,238
Other intangible assets, net	914,398	920,393
Deferred income taxes	4,388	4,152
Other assets	36,647	31,278
Total assets	2,847,058	2,848,345
Current liabilities:
Current portion of long-term debt	32,813	30,469
Accounts payable	104,372	83,517
Income taxes payable	12,549	13,477
Accrued expenses	74,992	81,540
Total current liabilities	224,726	209,003
Long-term debt	1,528,944	1,578,696
Deferred income taxes	150,578	145,364
Other long-term liabilities	22,421	21,901
Total liabilities	1,926,669	1,954,964
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 32,138,402 and 31,977,953 shares issued, respectively; 32,011,286 and 31,871,427 shares outstanding, respectively	32	32
Additional paid-in capital	673,106	669,756
Treasury stock, at cost, 127,116 and 106,526 shares, respectively	(5,964)	(4,654)
Retained earnings	184,186	176,068
Accumulated other comprehensive income	69,029	52,179
Total stockholders’ equity	920,389	893,381
Total liabilities and stockholders’ equity	$ 2,847,058	$ 2,848,345

Condensed Consolidated Balance Sheets - Unaudited (Parenthetical) - USD ($) $ in Millions	Mar. 30, 2018	Dec. 29, 2017
Current assets:
Allowance for doubtful accounts	$ 0.7	$ 0.8
Stockholders’ equity:
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	32,138,402	31,977,953
Common stock, shares outstanding	32,011,286	31,871,427
Treasury stock, shares	127,116	106,526

Condensed Consolidated Statements of Operations and Comprehensive Income - Unaudited - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Income Statement [Abstract]
Sales	$ 381,745	$ 345,413
Cost of sales	285,975	254,187
Gross profit	95,770	91,226
Operating expenses:
Selling, general and administrative expenses	41,238	39,499
Research, development and engineering costs	14,538	13,411
Other operating expenses	5,277	11,771
Total operating expenses	61,053	64,681
Operating income	34,717	26,545
Interest expense	26,445	28,893
(Gain) loss on cost and equity method investments, net	(4,970)	398
Other loss, net	1,033	1,449
Income (loss) before income taxes	12,209	(4,195)
Provision for income taxes	4,091	144
Net income (loss)	$ 8,118	$ (4,339)
Earnings (loss) per share:
Basic (in dollars per share)	$ 0.25	$ (0.14)
Diluted (in dollars per share)	$ 0.25	$ (0.14)
Weighted average shares outstanding:
Basic (in shares)	31,902	31,016
Diluted (in shares)	32,423	31,016
Comprehensive Income
Net income (loss)	$ 8,118	$ (4,339)
Foreign currency translation gain	13,441	6,536
Net change in cash flow hedges, net of tax	3,409	1,750
Other comprehensive income	16,850	8,286
Comprehensive income	$ 24,968	$ 3,947

Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net income (loss)	$ 8,118	$ (4,339)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	26,334	24,606
Debt related amortization included in interest expense	2,871	3,437
Stock-based compensation	3,222	4,669
Non-cash (gain) loss on cost and equity method investments	(4,970)	398
Other non-cash losses	123	1,101
Deferred income taxes	3,181	(1,753)
Changes in operating assets and liabilities:
Accounts receivable	1,008	(8,700)
Inventories	(11,442)	(5,956)
Prepaid expenses and other current assets	2,810	1,853
Accounts payable	22,466	13,146
Accrued expenses	(6,031)	4,401
Income taxes	(1,568)	5,762
Net cash provided by operating activities	46,122	38,625
Cash flows from investing activities:
Acquisition of property, plant and equipment	(10,959)	(12,787)
Proceeds from Sale of Property, Plant, and Equipment	898	459
Purchase of cost and equity method investments	0	(260)
Net cash used in investing activities	(10,061)	(12,588)
Cash flows from financing activities:
Principal payments of long-term debt	(50,032)	(79,151)
Proceeds from issuance of long-term debt	0	50,000
Proceeds from the exercise of stock options	1,006	7,449
Payment of debt issuance costs	0	(1,789)
Withholding tax paid related to stock-based compensation	(2,188)	0
Net cash used in financing activities	(51,214)	(23,491)
Effect of foreign currency exchange rates on cash and cash equivalents	545	219
Net increase (decrease) in cash and cash equivalents	(14,608)	2,765
Cash and cash equivalents, beginning of period	44,096	52,116
Cash and cash equivalents, end of period	29,488	54,881
Noncash investing and financing activities:
Property, plant and equipment purchases included in accounts payable	$ 2,007	$ 3,243

Condensed Consolidated Statement of Stockholders' Equity - Unaudited - 3 months ended Mar. 30, 2018 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance, shares at Dec. 29, 2017		31,978		107
Balance at Dec. 29, 2017	$ 893,381	$ 32	$ 669,756	$ (4,654)	$ 176,068	$ 52,179
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	8,118				8,118
Other comprehensive income, net	16,850					16,850
Stock-based compensation	3,222		3,222
Net shares issued, shares		160		(20)
Net shares issued	(1,182)	$ 0	128	$ (1,310)
Balance, shares at Mar. 30, 2018		32,138		127
Balance at Mar. 30, 2018	$ 920,389	$ 32	$ 673,106	$ (5,964)	$ 184,186	$ 69,029

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 30, 2018
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, orthopedics, vascular, advanced surgical and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in the energy, military, and environmental markets. The Company’s reportable segments are: (1) Medical and (2) Non-Medical. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Intercompany transactions and balances have been fully eliminated in consolidation. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 29, 2017. The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The first quarter of 2018 and 2017 each contained 13 weeks and ended on March 30, and March 31, respectively. The Company’s 2018 and 2017 fiscal years will end or ended on December 28, 2018 and December 29, 2017, respectively.

Inventories

3 Months Ended

Mar. 30, 2018

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are comprised of the following (in thousands):



	March 30, 2018		December 29, 2017
Raw materials	$	96,405	$	97,615
Work-in-process	104,612		92,650
Finished goods	38,473		37,269
Total	$	239,490	$	227,534

Goodwill and Other Intangible Assets, Net

3 Months Ended

Mar. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND OTHER INTANGIBLE ASSETS, NET

Goodwill

The changes in the carrying amount of goodwill by reportable segment for the quarter ended March 30, 2018 were as follows (in thousands):



	Medical		Non- Medical		Total
December 29, 2017	$	973,238	$	17,000	$	990,238
Foreign currency translation	4,962		—		4,962
March 30, 2018	$	978,200	$	17,000	$	995,200

Intangible Assets

Intangible assets at March 30, 2018 and December 29, 2017 were as follows (in thousands):



	Gross Carrying Amount		Accumulated Amortization			Foreign Currency Translation		Net Carrying Amount
March 30, 2018
Definite-lived:
Purchased technology and patents	$	256,719	$	(121,802	)	$	3,432	$	138,349
Customer lists	759,987		(95,149		)	20,872		685,710
Other	4,534		(7,809		)	3,326		51
Total	$	1,021,240	$	(224,760	)	$	27,630	$	824,110
Indefinite-lived:
Trademarks and tradenames								$	90,288

December 29, 2017
Definite-lived:
Purchased technology and patents	$	256,719	$	(117,695	)	$	2,483	$	141,507
Customer lists	759,987		(87,555		)	16,103		688,535
Other	4,534		(7,797		)	3,326		63
Total	$	1,021,240	$	(213,047	)	$	21,912	$	830,105
Indefinite-lived:
Trademarks and tradenames								$	90,288

Aggregate intangible asset amortization expense is comprised of the following (in thousands):



	Three Months Ended
	March 30, 2018		March 31, 2017
Cost of sales	$	4,068	$	4,084
Selling, general and administrative expenses	7,606		6,758
Research, development and engineering costs	39		136
Total intangible asset amortization expense	$	11,713	$	10,978

Estimated future intangible asset amortization expense based on the carrying value as of March 30, 2018 is as follows (in thousands):



	2018		2019		2020		2021		2022		After 2022
Amortization Expense	$	33,872	$	45,724	$	46,349	$	45,470	$	43,430	$	609,265

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Debt

3 Months Ended

Mar. 30, 2018

Debt Disclosure [Abstract]

DEBT

Long-term debt is comprised of the following (in thousands):



	March 30, 2018			December 29, 2017
Senior secured term loan A	$	328,125		$	335,157
Senior secured term loan B	830,286			873,286
9.125% senior notes due 2023	360,000			360,000
Revolving line of credit	74,000			74,000
Unamortized discount on term loan B and debt issuance costs	(30,654		)	(33,278		)
Total debt	1,561,757			1,609,165
Current portion of long-term debt	(32,813		)	(30,469		)
Total long-term debt	$	1,528,944		$	1,578,696

Senior Secured Credit Facilities

The Company has senior secured credit facilities (the “Senior Secured Credit Facilities”) consisting of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), (ii) a $375 million term loan A facility (the “TLA Facility”), and (iii) a $1,025 million term loan B facility (the “TLB Facility”). The TLA Facility and TLB Facility are collectively referred to as the “Term Loan Facilities.” The TLB facility was issued at a 1% discount.

Revolving Credit Facility

The Revolving Credit Facility matures on October 27, 2020. The Revolving Credit Facility also includes a $15 million sublimit for swingline loans and a $25 million sublimit for standby letters of credit. The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.175% and 0.25%, depending on the Company’s Total Net Leverage Ratio (as defined in the Senior Secured Credit Facilities agreement). Interest rates on the Revolving Credit Facility, as well as the TLA Facility, are at the Company’s option, either at: (i) the prime rate plus the applicable margin, which will range between 0.75% and 2.25%, based on the Company’s Total Net Leverage Ratio, or (ii) the applicable LIBOR rate plus the applicable margin, which will range between 1.75% and 3.25%, based on the Company’s Total Net Leverage Ratio.

As of March 30, 2018, the Company had $74 million of outstanding borrowings on the Revolving Credit Facility and an available borrowing capacity of $116.8 million after giving effect to $9.2 million of outstanding standby letters of credit. As of March 30, 2018, the weighted average interest rate on all outstanding borrowings under the Revolving Credit Facility was 5.10%.

Subject to certain conditions, commitments under the Revolving Credit Facility may be increased through an incremental revolving facility so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25:1.00. The outstanding amount of the Revolving Credit Facility approximated its fair value as of March 30, 2018 based upon the debt being variable rate and short-term in nature.

Term Loan Facilities

The TLA Facility and TLB Facility mature on October 27, 2021 and October 27, 2022, respectively. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the prime rate plus 2.25% or (ii) the applicable LIBOR rate plus 3.25%, with LIBOR subject to a 1.00% floor. As of March 30, 2018, the interest rates on the TLA Facility and TLB Facility were 5.13% and 4.99%, respectively. Additionally, if the Company receives both (a) a public corporate family credit rating from Moody’s Investors Services, Inc. of “B2” (stable outlook) or higher and (b) a public corporate credit rating from Standard & Poor’s Financial Services LLC of “B” (stable outlook) or higher, the interest rate margins for the TLB Facility will step down by an additional 25 basis points.

Subject to certain conditions, one or more incremental term loan facilities may be added to the Term Loan Facilities so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25:1.00.

As of March 30, 2018, the estimated fair value of the TLB Facility was approximately $839 million, based on quoted market prices for the debt, recent sales prices for the debt and consideration of comparable debt instruments with similar interest rates and trading frequency, among other factors, and is classified as Level 2 measurements within the fair value hierarchy. The par amount of the TLA Facility approximated its fair value as of March 30, 2018 based upon the debt being variable rate in nature.

(4.) DEBT (Continued)

Covenants

The Revolving Credit Facility and TLA Facility contain covenants requiring (A) a maximum Total Net Leverage Ratio of 6.0:1.00, subject to periodic step downs beginning in the third quarter of 2018 and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of not less than 2.75:1.00 subject to a step up beginning in the first quarter of 2019. As of March 30, 2018, the Company was in compliance with these financial covenants. The TLB Facility does not contain any financial maintenance covenants.

The Senior Secured Credit Facilities also contain negative covenants that restrict the Company’s ability to (i) incur additional indebtedness; (ii) create certain liens; (iii) consolidate or merge; (iv) sell assets, including capital stock of the Company’s subsidiaries; (v) engage in transactions with the Company’s affiliates; (vi) create restrictions on the payment of dividends or other amounts from the Company’s restricted subsidiaries; (vii) pay dividends on capital stock or redeem, repurchase or retire capital stock; (viii) pay, prepay, repurchase or retire certain subordinated indebtedness; (ix) make investments, loans, advances and acquisitions; (x) make certain amendments or modifications to the organizational documents of the Company or its subsidiaries or the documentation governing other senior indebtedness of the Company; and (xi) change the Company’s type of business. These negative covenants are subject to a number of limitations and exceptions that are described in the Senior Secured Credit Facilities agreement. As of March 30, 2018, the Company was in compliance with all negative covenants under the Senior Secured Credit Facilities.

The Senior Secured Credit Facilities provide for customary events of default. Upon the occurrence and during the continuance of an event of default, the outstanding advances and all other obligations under the Senior Secured Credit Facilities become immediately due and payable.

9.125% Senior Notes due 2023

On October 27, 2015, the Company completed a private offering of $360 million aggregate principal amount of 9.125% senior notes due on November 1, 2023 (the “Senior Notes”). All of the Senior Notes are outstanding as of March 30, 2018.

As of March 30, 2018, the estimated fair value of the Senior Notes was approximately $390 million, based on quoted market prices of these Senior Notes, recent sales prices for the Senior Notes and consideration of comparable debt instruments with similar interest rates and trading frequency, among other factors, and is classified as Level 2 measurements within the fair value hierarchy.

The indenture for the Senior Notes contain certain restrictive covenants and provides for customary events of default, subject in certain cases to customary cure periods, as a result of which the Senior Notes and any unpaid interest would become due and payable. As of March 30, 2018, the Company was in compliance with all restrictive covenants under the indenture governing the Senior Notes.

Contractual maturities under the Senior Secured Credit Facilities and Senior Notes for the remainder of 2018 and the next four years and thereafter, excluding any discounts or premiums, as of March 30, 2018 are as follows (in thousands):



	2018		2019		2020		2021		2022		After 2022
Future minimum principal payments	$	23,437	$	37,500	$	111,500	$	229,688	$	830,286	$	360,000

Debt Issuance Costs and Discounts

The change in deferred debt issuance costs related to the Revolving Credit Facility is as follows (in thousands):



December 29, 2017	$	2,808
Amortization during the period	(247		)
March 30, 2018	$	2,561

(4.) DEBT (Continued)

The change in unamortized discount and debt issuance costs related to the Term Loan Facilities and Senior Notes is as follows (in thousands):



	Debt Issuance Costs			Unamortized Discount on TLB Facility			Total
December 29, 2017	$	26,889		$	6,389		$	33,278
Write-off of debt issuance costs and unamortized discount⁽¹⁾	(745		)	(312		)	(1,057		)
Amortization during the period	(1,279		)	(288		)	(1,567		)
March 30, 2018	$	24,865		$	5,789		$	30,654

⁽¹⁾

The Company prepaid portions of its TLB Facility during 2018 and 2017. The Company recognized losses from extinguishment of debt during the quarters ended March 30, 2018 and March 31, 2017 of $1.1 million and $1.6 million, respectively, which is included in Interest Expense in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income. The loss from extinguishment of debt represents the portion of the unamortized discount and debt issuance costs related to the portion of the TLB Facility that was prepaid.

Interest Rate Swap

During 2016, the Company entered into a three-year $200 million interest rate swap to hedge against potential changes in cash flows on the outstanding variable rate debt, which is indexed to the one-month LIBOR rate. The variable rate received on the interest rate swap and the variable rate paid on the outstanding debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The swap is being accounted for as a cash flow hedge.

Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of March 30, 2018 is as follows (dollars in thousands):



Notional Amount		Start Date	End Date	Pay Fixed Rate		Receive Current Floating Rate		Fair Value		Balance Sheet Location
$	200,000	Jun-17	Jun-20	1.1325	%	1.8750	%	$	5,544	Other Long-Term Assets

The estimated fair value of the interest rate swap agreement represents the amount the Company would receive (pay) to terminate the contract. No portion of the change in fair value of the Company’s interest rate swap during the quarters ended March 30, 2018 and March 31, 2017 was considered ineffective. The amounts recorded to Interest Expense during the quarters ended March 30, 2018 and March 31, 2017 related to the Company’s interest rate swap were a reduction of $0.2 million and $0.1 million, respectively. The estimated Accumulated Other Comprehensive Income related to the Company’s interest rate swaps that is expected to be reclassified into earnings within the next twelve months is a $2.0 million gain.

Benefit Plans

3 Months Ended

Mar. 30, 2018

Defined Benefit Plan [Abstract]

BENEFIT PLANS

The Company is required to provide its employees located in Switzerland, Mexico, France, and Germany certain statutorily mandated defined benefits. Components of net defined benefit cost for these plans were comprised of the following (in thousands):



	Three Months Ended
	March 30, 2018			March 31, 2017
Service cost	$	127		$	110
Interest cost	46			38
Amortization of net loss	16			17
Expected return on plan assets	(4		)	(4		)
Net defined benefit cost	$	185		$	161

Stock-Based Compensation

3 Months Ended

Mar. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors, or the Compensation and Organization Committee of the Board. The stock-based compensation plans provide for the granting of stock options, shares of restricted stock awards (“RSAs”), restricted stock units (“RSUs”), stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers.

The components and classification of stock-based compensation expense were as follows (in thousands):



	Three Months Ended
	March 30, 2018		March 31, 2017
Stock options	$	331	$	710
RSAs and RSUs (time-based)	2,078		2,204
Performance-based RSUs (“PSUs”)	813		1,755
Total stock-based compensation expense	$	3,222	$	4,669

Cost of sales	$	220	$	142
Selling, general and administrative expenses	2,965		2,159
Research, development and engineering costs	33		105
Other operating expenses	4		2,263
Total stock-based compensation expense	$	3,222	$	4,669

During the first quarter of 2017, the Company recorded $2.2 million of accelerated stock-based compensation expense in connection with the transition of its former Chief Executive Officer per the terms of his contract, which was classified as Other Operating Expenses.

The weighted average fair value and assumptions used to value options granted are as follows:



	Three Months Ended
	March 30, 2018			March 31, 2017
Weighted average fair value	$	14.89		$	9.14
Risk-free interest rate	2.21		%	1.63		%
Expected volatility	39		%	38		%
Expected life (in years)	4.0			3.7
Expected dividend yield	—		%	—		%

The following table summarizes the Company’s stock option activity:



	Number of Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (In Years)	Aggregate Intrinsic Value (In Millions)
Outstanding at December 29, 2017	931,353		$	30.89
Granted	28,447		45.13
Exercised	(27,322	)	36.81
Forfeited or expired	(818	)	48.43
Outstanding at March 30, 2018	931,660		$	31.14	5.7	$	23.7
Exercisable at March 30, 2018	777,521		$	30.03	5.0	$	20.6

(6.) STOCK-BASED COMPENSATION (Continued)

During the three months ended March 30, 2018, the Company awarded grants of 0.3 million RSUs to certain members of management, of which 0.2 million are performance-based RSUs (“PSUs”) and the remainder are time-based RSUs that vest over three years. Of the PSUs, 0.1 million of the shares subject to each grant will be earned based upon achievement of specific Company performance metrics over a three-year performance period ending January 1, 2021, and 0.1 million of the shares subject to each grant will be earned based on the Company’s achievement of a relative total shareholder return (“TSR”) performance requirement, on a percentile basis, compared to a defined group of peer companies over a three-year performance period ending January 1, 2021. The number of PSUs earned based on the achievement of the Company performance metrics and TSR performance requirements, if any, will vest based on the recipient’s continuous service to the Company over a period of generally one to three years from the grant date. The time-based RSUs generally vest ratably over a three-year period.

The grant-date fair value of the TSR portion of the PSUs granted during the three months ended March 30, 2018 was determined using the Monte Carlo simulation model on the date of grant, assuming the following (i) expected term of 2.92 years, (ii) risk free interest rate of 2.28%, (iii) expected dividend yield of 0.0% and (iv) expected stock price volatility over the expected term of the TSR award of 40%. The grant-date fair value of all other restricted stock awards is equal to the closing market price of Integer common stock on the date of grant.

The following table summarizes RSA and RSU activity:



	Time-Vested Activity		Weighted Average Fair Value
Nonvested at December 29, 2017	163,431		$	35.96
Granted	147,878		49.30
Vested	(11,999	)	49.78
Forfeited	(4,453	)	43.62
Nonvested at March 30, 2018	294,857		$	41.97

The following table summarizes PSU activity:



	Performance- Vested Activity		Weighted Average Fair Value
Nonvested at December 29, 2017	469,889		$	32.37
Granted	159,669		45.37
Vested	(127,191	)	34.29
Forfeited	(129,311	)	33.36
Nonvested at March 30, 2018	373,056		$	36.93

Other Operating Expenses, Net

3 Months Ended

Mar. 30, 2018

Other Income and Expenses [Abstract]

OTHER OPERATING EXPENSES, NET

OTHER OPERATING EXPENSES

Other Operating Expenses is comprised of the following (in thousands):



	Three Months Ended
	March 30, 2018		March 31, 2017
Strategic reorganization and alignment	$	3,492	$	—
Manufacturing alignment to support growth	513		—
Consolidation and optimization initiatives	605		2,395
Acquisition and integration expenses	—		4,820
Asset dispositions, severance and other	667		4,556
Total other operating expenses	$	5,277	$	11,771

(7.) OTHER OPERATING EXPENSES (Continued)

Strategic Reorganization and Alignment

During the fourth quarter of 2017, the Company began to take steps to better align its resources in order to enhance the profitability of its portfolio of products. This includes improving its business processes and redirecting investments away from projects where the market does not justify the investment, as well as aligning resources with market conditions and the Company’s future strategic direction. The Company estimates that it will incur aggregate pre-tax charges in connection with the strategic reorganization and alignment plan of between approximately $10 million to $12 million, of which an estimated $8 million to $12 million are expected to result in cash outlays. During the three months ended March 30, 2018, the Company incurred charges relating to this initiative which primarily included severance and personnel related costs for terminated employees and fees for professional services. These expenses were primarily recorded within the Medical Segment. As of March 30, 2018, total expense incurred for this initiative since inception was $9.4 million. These actions are expected to be substantially completed by the end of the second quarter of 2018.

Manufacturing Alignment to Support Growth

In 2017, the Company initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of the Company's facilities. The Company estimates that it will incur aggregate pre-tax restructuring related charges in connection with the realignment plan of between approximately $9 million to $11 million, the majority of which are expected to be cash expenditures, and capital expenditures of between approximately $4 million to $6 million. Costs related to the Company’s manufacturing alignment to support growth initiative were primarily recorded within the Medical Segment. As of March 30, 2018, total expense incurred for this initiative since inception was $0.9 million. These actions are expected to be substantially completed by the end of 2019.

Consolidation and Optimization Initiatives

In 2014, the Company initiated plans to transfer certain manufacturing functions performed at its facility in Beaverton, OR to a new facility in Tijuana, Mexico. Additionally, during 2016, the Company announced it would be closing its facility in Clarence, NY after transferring the machined component product lines manufactured in that facility to other Integer locations in the U.S. Costs related to the Company’s consolidation and optimization initiatives were primarily recorded within the Medical Segment. The Company does not expect to incur any material additional costs associated with these activities as they were substantially completed as of March 30, 2018.

The following table summarizes the change in accrued liabilities related to the initiatives described above (in thousands):



	Severance and Retention			Other			Total
December 29, 2017	$	1,308		$	—		$	1,308
Restructuring charges	3,274			1,336			4,610
Cash payments	(3,136		)	(897		)	(4,033		)
March 30, 2018	$	1,446		$	439		$	1,885

Acquisition and Integration Expenses

The Company did not incur any additional costs associated with these activities during the three months ended March 30, 2018. During the three months ended March 31, 2017, the Company incurred $4.8 million in acquisition and integration costs related to the acquisition of Lake Region Medical, consisting primarily of integration costs. Integration costs primarily include professional, consulting, severance, retention, relocation, and travel costs. The $0.4 million of acquisition and integration costs accrued as of December 29, 2017 were paid during the three months ended March 30, 2018. These projects were completed as of December 29, 2017.

Asset Dispositions, Severance and Other

During the first quarter of 2018 and 2017, the Company recorded losses in connection with various asset disposals and/or write-downs. The 2017 amount also includes approximately $4.7 million in expense related to the Company’s leadership transitions, which were recorded within the corporate unallocated segment.

Income Taxes	3 Months Ended
Income Taxes	Mar. 30, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix and amount of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Reform Act”) was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S international taxation from a worldwide tax system to a territorial system, and a one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017. Under GAAP, the effect of a change in tax laws or rates to be recognized in income from continuing operations for the period that includes the enactment date. As such, the Company recognized an estimate of the impact of the Tax Reform Act in the year ended December 29, 2017. The Company had an estimated $147.5 million of undistributed foreign earnings and profit subject to the deemed mandatory repatriation as of December 29, 2017 and recognized a provisional $14.7 million in 2017 for the one-time transition tax. The Company has sufficient U.S. net operating losses to offset cash tax liabilities associated with the repatriation tax. In addition, as a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Reform Act, the Company revalued its ending net deferred tax liabilities at December 29, 2017 and recognized a $56.5 million tax benefit in the Company’s Consolidated Statement of Operations and Comprehensive Income (Loss) for the year ended December 29, 2017. For further discussion of the impact of the Tax Reform Act for the year ended December 29, 2017 reference is made to Note 12 of the Company’s consolidated financial statements as of and for the year ended December 29, 2017 included in the Company’s 2017 Annual Report on Form 10-K for the year ended December 29, 2017. On December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin (“SAB”) No. 118 to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Reform Act. The Company recognized the tax impact of the revaluation of deferred tax assets and liabilities and the provisional tax impact related to deemed repatriated earnings and included these amounts in its consolidated financial statements for the year ended December 29, 2017. The ultimate impact may differ from the provisional amount, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Reform Act. This accounting is expected to be complete by the date that the Company’s 2017 U.S. corporate income tax return is filed in 2018. During the three month period ended March 30, 2018, there were no changes made to the provisional amount recorded in 2017. In addition to the reduction of the U.S. federal corporate tax rate and the one-time transition tax discussed above, the Tax Reform Act also established new tax laws that affect 2018, including, but not limited to: (i) a general elimination of U.S. federal income taxes on dividends from foreign subsidiaries; (ii) a new U.S. Income inclusion on certain earnings of foreign subsidiaries (Global Intangible Low-Taxed Income (“GILTI”)); (iii) the repeal of the domestic production activity deductions; (iv) limitations on the deductibility of certain executive compensation; (v) an elimination of the deduction for certain deemed “base erosion payments” made to foreign affiliates (Base Erosion and Anti-Abuse Tax (“BEAT”)); and (vi) a new provision that allows a domestic corporation an immediate deduction for a portion of its foreign derived intangible income (“FDII”). (8.) INCOME TAXES (Continued) The GILTI provisions require the Company to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in its U.S. income tax return. The Company expects that it will be subject to incremental U.S. tax on GILTI income beginning in 2018. Because of the complexity of the new GILTI tax rules and the ongoing regulatory interpretation of the GILTI provisions, the Company is continuing its evaluation of this provision of the Tax Reform Act and the application of ASC 740, Income Taxes. Under GAAP, the Company is allowed to make an accounting policy choice of either (1) treating taxes due on future U.S. inclusions in taxable income related to GILTI as a current period expense when incurred (the “period cost method”) or (2) factoring such amounts into the Company's measurement of its deferred taxes (the “deferred method”). The Company's selection of an accounting policy with respect to the new GILTI tax rules will depend, in part, on analyzing its global income to determine whether it expects to have future U.S. inclusions in taxable income related to GILTI and, if so, what the impact is expected to be. Whether the Company expects to have future U.S. inclusions in taxable income related to GILTI depends on not only the Company's current structure and estimated future results of global operations, but also its intent and ability to modify its structure. While the Company has included an estimate of GILTI in its estimated effective tax rate for 2018, it has not finalized its analysis and is not yet able to determine which method to elect. Adjustments related to the amount of GILTI Tax recorded in its condensed consolidated financial statements may be required based on the outcome of this election. The BEAT provisions in the Tax Reform Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum tax if greater than regular tax. The Company does not expect to be materially impacted by the BEAT or FDII provisions and has not included any impact of the provisions in its estimated effective tax rate for 2018, however, it is still in the process of analyzing the effect of these provisions of the Tax Reform Act. The Company’s worldwide effective tax rate for the first quarter of 2018 was 33.5% on $12.2 million of income before the provision for income taxes compared to (3.4)% on $4.2 million of losses before the provision for income taxes for the same period in 2017. The 2018 estimated annual effective tax rate includes the estimated impact of all Tax Reform Act provisions. The Company’s effective tax rate for 2018 differs from the U.S. federal statutory tax rate of 21% due principally to the estimated impact of the GILTI tax. The Company’s earnings outside the United States are generally taxed at blended rates that are marginally lower than the U.S. federal rate. The GILTI provisions require the Company to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in its U.S. income tax return. There is a statutory deduction of 50% of the GILTI inclusion, however the deduction is subject to limitations based on U.S. taxable income. The Company currently has net operating losses to offset forecasted U.S. taxable income and as such, is temporarily subject to the deduction limitation which correspondingly imposes an incremental impact on U.S. income tax. The foreign jurisdictions in which the Company operates and where its foreign earnings are primarily derived, include Switzerland, Mexico, Germany, Uruguay, Malaysia and Ireland. The Company’s effective tax rate for 2017 differs from the U.S. federal statutory tax rate of 35% due principally to the Company’s earnings outside the U.S. which are generally taxed at rates lower than the U.S. federal rate. In addition, the Company had positive income before taxes in its foreign jurisdictions but losses before taxes in U.S. jurisdictions. As of March 30, 2018, the balance of unrecognized tax benefits is approximately $12.7 million. It is reasonably possible that a reduction of up to $1.1 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of potential audit settlements. Approximately $12.3 million of the balance of unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized.

Commitments and Contingencies

3 Months Ended

Mar. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

Litigation

The Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, will not become material in the future.

(9.) COMMITMENTS AND CONTINGENCIES

In April 2013, the Company commenced an action against AVX Corporation and AVX Filters Corporation (collectively “AVX”) alleging that AVX had infringed on the Company’s patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate the Company’s patented technology. On January 26, 2016, a jury in the U.S. District Court for the District of Delaware returned a verdict finding that AVX infringed two Integer patents and awarded Integer $37.5 million in damages. Following a second trial in August 2017, a jury found that AVX infringed an additional Integer patent. On March 30, 2018, the U.S. District Court for the District of Delaware vacated the original damage award and ordered a retrial on damages, which is scheduled for January 2019. The Company has recorded no gains in connection with this litigation as no cash has been received.

Product Warranties

The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The Company does not expect future product warranty claims will have a material effect on its condensed consolidated results of operations, financial position, or cash flows. However, there can be no assurance that any future customer complaints or negative regulatory actions regarding the Company’s products, which the Company currently believes to be immaterial, does not become material in the future. The change in product warranty liability was comprised of the following (in thousands):



December 29, 2017	$	4,745
Additions to warranty reserve	256
Warranty claims settled	(69		)
March 30, 2018	$	4,932

Foreign Currency Contracts

The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations. The Company has designated these foreign currency forward contracts as cash flow hedges. Accordingly, the effective portions of the unrealized gains and losses on these contracts are reported in Accumulated Other Comprehensive Income in the Condensed Consolidated Balance Sheets and are reclassified to earnings in the same periods during which the hedged transactions affect earnings. The estimated Accumulated Other Comprehensive Income related to the Company’s foreign currency contracts that is expected to be reclassified into earnings within the next twelve months is a $2.2 million loss.

The impact to the Company’s results of operations from its forward contract hedges is as follows (in thousands):



	Three Months Ended
	March 30, 2018			March 31, 2017
Increase in sales	$	139		$	24
Increase (decrease) in cost of sales	(436		)	1,062
Ineffective portion of change in fair value	—			—

Information regarding outstanding foreign currency contracts designated as cash flow hedges as of March 30, 2018 is as follows (dollars in thousands):

Aggregate

Notional

Amount

Start

Date

End

Date

$/Foreign Currency

Fair

Value

Balance Sheet Location

$

2,313

Jan 2018

Jun 2018

0.0514

Peso

$

142

Prepaid expenses and other current assets

22,798

Jan 2018

Dec 2018

0.0507

Peso

1,403

Prepaid expenses and other current assets

21,900

Jan 2018

Dec 2018

1.2089

Euro

644

Prepaid expenses and other current assets

Earnings (Loss) Per Share (EPS)

3 Months Ended

Mar. 30, 2018

Earnings Per Share [Abstract]

EARNINGS (LOSS) PER SHARE (EPS)

EARNINGS (LOSS) PER SHARE (“EPS”)

The following table illustrates the calculation of basic and diluted EPS (in thousands, except per share amounts):



	Three Months Ended
	March 30, 2018		March 31, 2017
Numerator for basic and diluted EPS:
Net income (loss)	$	8,118	$	(4,339	)
Denominator for basic EPS:
Weighted average shares outstanding	31,902		31,016
Effect of dilutive securities:
Stock options, restricted stock and RSUs	521		—
Denominator for diluted EPS	32,423		31,016
Basic EPS	$	0.25	$	(0.14	)
Diluted EPS	$	0.25	$	(0.14	)

The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):



	Three Months Ended
	March 30, 2018	March 31, 2017
Time-vested stock options, restricted stock and RSUs	150	1,700
Performance-vested restricted stock and PSUs	182	593

Accumulated Other Comprehensive Income (Loss)

3 Months Ended

Mar. 30, 2018

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

ACCUMULATED OTHER COMPREHENSIVE INCOME

Accumulated Other Comprehensive Income is comprised of the following (in thousands):



	Defined Benefit Plan Liability			Cash Flow Hedges			Foreign Currency Translation Adjustment		Total Pre-Tax Amount			Tax			Net-of-Tax Amount
December 29, 2017	$	(1,422	)	$	3,418		$	50,200	$	52,196		$	(17	)	$	52,179
Unrealized gain on cash flow hedges	—			5,124			—		5,124			(1,076		)	4,048
Realized gain on foreign currency hedges	—			(575		)	—		(575		)	121			(454		)
Realized gain on interest rate swap hedges	—			(234		)	—		(234		)	49			(185		)
Foreign currency translation gain	—			—			13,441		13,441			—			13,441
March 30, 2018	$	(1,422	)	$	7,733		$	63,641	$	69,952		$	(923	)	$	69,029



December 30, 2016	$	(1,475	)	$	1,420		$	(15,660	)	$	(15,715	)	$	(285	)	$	(16,000	)
Unrealized gain on cash flow hedges	—			1,712			—			1,712			(599		)	1,113
Realized loss on foreign currency hedges	—			1,086			—			1,086			(380		)	706
Realized gain on interest rate swap hedges	—			(106		)	—			(106		)	37			(69		)
Foreign currency translation gain	—			—			6,536			6,536			—			6,536
March 31, 2017	$	(1,475	)	$	4,112		$	(9,124	)	$	(6,487	)	$	(1,227	)	$	(7,714	)

The realized loss (gain) relating to the Company’s foreign currency hedges were reclassified from Accumulated Other Comprehensive Income and included in Cost of Sales or Sales as the transactions they are hedging occur. The realized gain relating to the Company’s interest rate swap hedges were reclassified from Accumulated Other Comprehensive Income and included in Interest Expense as interest on the corresponding debt being hedged is accrued.

Fair Value Measurements

3 Months Ended

Mar. 30, 2018

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

Assets and Liabilities Measured at Fair Value on a Recurring Basis

Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis. The Company also holds cost method and equity method investments which are measured at fair value on a nonrecurring basis.

Foreign Currency Contracts

The fair value of foreign currency contracts were determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs included foreign exchange rate and credit spread curves. In addition, the Company received fair value estimates from the foreign currency contract counterparties to verify the reasonableness of the Company’s estimates. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. Refer to Note 9 “Commitments and Contingencies” for further discussion regarding the fair value of the Company’s foreign currency contracts.

Interest Rate Swaps

The fair value of the Company’s interest rate swap contracts outstanding were determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. In addition, the Company received a fair value estimate from the interest rate swap counterparty to verify the reasonableness of the Company’s estimate. Refer to Note 4 “Debt” for further discussion regarding the fair value of the Company’s interest rate swap.

The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):



	Fair Value		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
March 30, 2018
Assets: Foreign currency contracts (Note 9)	$	2,189	$	—	$	2,189	$	—
Assets: Interest rate swap (Note 4)	5,544		—		5,544		—

December 29, 2017
Assets: Interest rate swaps	$	4,279	$	—	$	4,279	$	—
Liabilities: Foreign currency contracts	861		—		861		—

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items. Refer to Note 4 “Debt” for further discussion regarding the fair value of the Company’s Senior Secured Credit Facilities and Senior Notes. A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows:

Cost and Equity Method Investments

The Company holds investments in equity and other securities that are accounted for as either cost method or equity method investments, which are classified as Other Assets on the Condensed Consolidated Balance Sheets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost method investments are not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. The aggregate recorded amount of cost and equity method investments at March 30, 2018 and December 29, 2017 was $25.8 million and $20.8 million, respectively.

(12.) FAIR VALUE MEASUREMENTS (Continued)

As of March 30, 2018 and December 29, 2017, the recorded amount of the Company’s equity method investment was $18.8 million and $13.8 million, respectively. The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. This fund accounts for its investments at fair value with the unrealized change in fair value of these investments recorded as income or loss to the fund in the period of change. As of March 30, 2018, the Company owned 6.6% of this fund. During the three months ended March 30, 2018 and March 31, 2017, the Company recognized a net gain of $5.0 million and a net loss of $0.4 million, respectively, on its equity method investment.

The Company’s recorded amount of cost method investments was $7.0 million at March 30, 2018 and December 29, 2017.

The Company did not recognize any impairment charges related to cost method investments during the three months ended March 30, 2018 and March 31, 2017. The fair value of these investments is primarily determined by reference to recent sales data of similar shares to independent parties in an inactive market and categorized in Level 2 of the fair value hierarchy.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Segment Information

3 Months Ended

Mar. 30, 2018

Segment Reporting [Abstract]

SEGMENT INFORMATION

The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker (“CODM”), to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting. There were no sales between segments during the three months ended March 30, 2018 and March 31, 2017.

The following table presents sales by product line (in thousands).



	Three Months Ended
	March 30, 2018		March 31, 2017
Segment sales by product line:
Medical
Cardio & Vascular	$	138,348	$	125,108
Cardiac & Neuromodulation	108,910		103,813
Advanced Surgical, Orthopedics & Portable Medical	121,775		105,146
Total Medical	369,033		334,067
Non-Medical	12,712		11,346
Total sales	$	381,745	$	345,413

The following table presents income from operations for the Company’s reportable segments (in thousands).



	Three Months Ended
	March 30, 2018			March 31, 2017
Segment income from operations:
Medical	$	52,127		$	50,360
Non-Medical	3,198			1,562
Total segment income from operations	55,325			51,922
Unallocated operating expenses	(20,608		)	(25,377		)
Operating income	34,717			26,545
Unallocated expenses, net	(22,508		)	(30,740		)
Income (loss) before income taxes	$	12,209		$	(4,195	)

Revenue From Contracts With Customers

3 Months Ended

Mar. 30, 2018

Revenue from Contract with Customer [Abstract]

REVENUE FROM CONTRACTS WITH CUSTOMERS

The majority of the Company’s revenues consist of sales of various medical devices and products to large, multinational OEMs and their affiliated subsidiaries. The Company considers the customer’s purchase order, which in some cases is governed by a long-term agreement, and the Company’s corresponding sales order acknowledgment as the contract with the customer. The Company has elected to adopt the practical expedient provided in ASC 340-40-25-4 and recognize the incremental costs of obtaining a contract, which are primarily sales commissions, as expense when incurred because the amortization period is less than one year.

Performance Obligations

The Company considers each shipment of an individual product included on a purchase order to be a separate performance obligation, as each shipment is separately identifiable and the customer can benefit from each individual product separately from the other products included on the purchase order. Accordingly, a contract can have one or more performance obligations to manufacture products. Standard payment terms range from 30 to 90 days and can include a discount for early payment.

The Company does not offer its customers a right of return. Rather, the Company warrants that each unit received by the customer will meet the agreed upon technical and quality specifications and requirements. Only when the delivered units do not meet these requirements can the customer return the non-compliant units as a corrective action under the warranty. The remedy offered to the customer is repair of the returned units or replacement if repair is not viable. Accordingly, the Company records a warranty reserve and any warranty activities are not considered to be a separate performance obligation. Historically, warranty reserves have not been material.

Transaction Price

Generally, the transaction price of the Company’s contracts consists of a unit price for each individual product included in the contract, which can be fixed or variable based on the number of units ordered. In some instances, the transaction price also includes a rebate for meeting certain volume-based targets over a specified period of time. The transaction price of a contract is determined based on the unit price and the number of units ordered, reduced by the rebate expected to be earned on those units. Rebates are estimated based on the expected achievement of the volume-based target using the most likely amount method and updated quarterly. Any adjustments to these estimates are recognized under the cumulative catch-up method, such that impact of the adjustment is recognized in the period in which it is identified.

The transaction price is allocated to each performance obligation on a relative standalone selling price basis. As the majority of products sold to customers are manufactured to meet the specific requirements and technical specifications of that customer, the products are considered unique to that customer and the unit price stated in the contract is considered the standalone selling price.

The Company has elected to adopt the practical expedient provided in ASC 606-10-50-14 and not disclose the aggregate amount of the transaction price allocated to unsatisfied performance obligations and an expectation of when those amounts are expected to be recognized as revenue because the majority of contracts have an original expected duration of one year or less.

Revenue Recognition

The Company recognizes revenue at the point in time when a performance obligation is satisfied and the customer has obtained control of the products. Control is defined as the ability to direct the use of and obtain substantially all of the remaining benefits of the product. The customer obtains control of the products when title and risk of ownership transfers to them, which is primarily based upon shipping terms. Accordingly, the majority of the Company’s revenues are recognized at the point of shipment. In instances where title and risk of ownership do not transfer to the customer until the products have reached the customer’s location, revenue is recognized at that point in time. Revenue is recognized net of sales tax, value-added taxes and other taxes.

Contract Modifications

Contract modifications, which can include a change in either or both scope and price, most often occur related to contracts that are governed by a long-term arrangement. Contract modifications typically relate to the same products already governed by the long-term arrangement, and therefore, are accounted for as part of the existing contract. If a contract modification is for additional products, it is accounted for as a separate contract.


(14.)	REVENUE FROM CONTRACTS WITH CUSTOMERS (Continued)

Disaggregated Revenue

In general, the Company's business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment's results of operations. For a summary by disaggregated product line sales for each segment, refer to Note 13, “Segment Information.” Additionally, the tables below disaggregate the Company’s revenues based upon significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues, and ship to country, which is defined as any country where 10% or more of a segment’s total revenues are shipped to. The Company believes that these categories best depict how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors.

The following table presents revenues by customer for the three months ended March 30, 2018.



Customer	Medical		Non-Medical
Customer A	17	%	—	%
Customer B	16	%	—	%
Customer C	15	%	—	%
Customer D	—	%	19	%
Customer E	—	%	11	%
All other customers	52	%	70	%

The following table presents revenues by ship to country for the three months ended March 30, 2018.



Ship to Location	Medical		Non-Medical
United States	55	%	69	%
Puerto Rico	10	%	—	%
Canada	—	%	11	%
All other Countries	35	%	20	%

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable and less frequently, unearned revenue. Accounts receivable are recorded when the right to consideration becomes unconditional. Unearned revenue is recorded when customers pay or are billed in advance of the Company’s satisfaction of performance obligations. Contract liabilities were $4.4 million and $3.6 million as of March 30, 2018 and December 29, 2017, respectively, and are classified as Accrued Expenses on the Condensed Consolidated Balance Sheets. During the three months ended March 30, 2018, we recognized $0.7 million of revenue that was included in the contract liability balance as of December 29, 2017. The Company does not have any contract assets.

Impact of Recently Issued Accounting Standards

3 Months Ended

Mar. 30, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS

The following table provides a brief description of recent Accounting Standard Updates ("ASU") issued by the Financial Accounting Standards Board ("FASB"):



Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.	The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users.	December 29, 2018 (beginning of 2019 fiscal year). Early adoption is permitted.	The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements.
In August 2017, the FASB issued ASU 2017-12, Targeted Improvements to Accounting for Hedging Activities.	The new guidance improves the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results.	December 29, 2018. Early adoption is permitted.	The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements.
In March 2017, the FASB issued ASU 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.	The new guidance clarifies the presentation and classification of the components of net periodic benefit costs in the consolidated statement of operations.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017, the beginning of its 2018 fiscal year, using the retrospective transition method, as part of the FASB's simplification initiative. See Adoption of ASU 2017-07 section below for additional information.
In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory.	The new guidance requires the income tax consequences of an intra-entity transfer of assets other than inventory to be recognized when the transfer occurs rather than deferring until an outside sale has occurred.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.
In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments.	The new guidance clarifies the presentation and classification of certain cash receipts and cash payments in the statement of cash flows.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.
In February 2016, the FASB issued ASU 2016-02, Leases.	The new guidance supersedes the lease guidance under ASC Topic 840, Leases, resulting in the creation of FASB ASC Topic 842, Leases. The guidance requires a lessee to recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term for both finance and operating leases.	December 29, 2018. Early adoption is permitted.	The Company is currently evaluating its population of leases, and is continuing to assess all potential impacts of the standard, but currently believes the most significant impact relates to its accounting for real estate operating leases. The Company anticipates recognition of additional assets and corresponding liabilities related to leases upon adoption, but has not yet quantified these at this time. The Company plans to adopt the standard effective December 29, 2018.

(15.) IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS (Continued)



Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities.	The new guidance updates certain aspects of recognition, measurement, presentation and disclosure of financial instruments.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. Since that date, the FASB has issued additional ASUs clarifying certain aspects of ASU 2014-09.	The new guidance requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance provides alternative methods of adoption. Subsequent guidance issued after May 2014 did not change the core principle of ASU 2014-09.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017, using the modified retrospective transition method applied to those contracts which were not completed as of December 30, 2017. Prior period amounts have not been adjusted and continue to be reflected in accordance with the Company’s historical accounting. The adoption of this ASU did not have a material impact on the consolidated financial statements and therefore no cumulative adjustment was recorded to equity. The Company has updated its internal controls for changes and expanded disclosures have been made in the Notes to the Financial Statements as a result of adopting the standard. (See Note 14, “Revenue from Contracts with Customers”).

Adoption of ASU 2017-07

On December 30, 2017, we retrospectively adopted the new accounting guidance on presentation of net periodic pension costs (ASU 2017-07). That guidance requires that we disaggregate the service cost component of net benefit costs and report those costs in the same line item or items in the Condensed Consolidated Statements of Operations and Comprehensive Income as other compensation costs arising from services rendered by the pertinent employees during the period. The other non-service components of net benefit costs are required to be presented separately from the service cost component.

Following the adoption of this guidance, we continue to record the service cost component of net benefit costs in Cost of Sales and Selling, General and Administrative expenses. The interest cost component of net benefit costs is now recorded in Interest Expense and the remaining components of net benefit costs, amortization of net losses and expected return on plan assets, are now recorded in Other Loss, Net.

Subsequent Event	3 Months Ended
Subsequent Event	Mar. 30, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENT	SUBSEQUENT EVENT On May 3, 2018, the Company entered into a definitive agreement to sell the Advanced Surgical and Orthopedic product lines within its Medical segment to MedPlast, LLC for $600 million in cash (the “Transaction”). The Company expects to close the Transaction in the third quarter of 2018, subject to regulatory clearance and other customary closing conditions. The net proceeds from the sale are expected to be used to accelerate debt payments to reduce leverage.

Basis of Presentation (Policies)	3 Months Ended
Basis of Presentation (Policies)	Mar. 30, 2018
Accounting Policies [Abstract]
Interim Basis of Accounting	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Intercompany transactions and balances have been fully eliminated in consolidation. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 29, 2017.
Use of Estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates.
Fiscal Period	The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The first quarter of 2018 and 2017 each contained 13 weeks and ended on March 30, and March 31, respectively.
Income Taxes	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix and amount of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations.
Cost And Equity Method Investments	The Company holds investments in equity and other securities that are accounted for as either cost method or equity method investments, which are classified as Other Assets on the Condensed Consolidated Balance Sheets.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

Inventories (Tables)

3 Months Ended

Mar. 30, 2018

Inventory Disclosure [Abstract]

Schedule of Inventory, Current

Inventories are comprised of the following (in thousands):



	March 30, 2018		December 29, 2017
Raw materials	$	96,405	$	97,615
Work-in-process	104,612		92,650
Finished goods	38,473		37,269
Total	$	239,490	$	227,534

Goodwill and Other Intangible Assets, Net (Tables)

3 Months Ended

Mar. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The changes in the carrying amount of goodwill by reportable segment for the quarter ended March 30, 2018 were as follows (in thousands):



	Medical		Non- Medical		Total
December 29, 2017	$	973,238	$	17,000	$	990,238
Foreign currency translation	4,962		—		4,962
March 30, 2018	$	978,200	$	17,000	$	995,200

Schedule of Finite-Lived Intangible Assets, Major Class

Intangible assets at March 30, 2018 and December 29, 2017 were as follows (in thousands):



	Gross Carrying Amount		Accumulated Amortization			Foreign Currency Translation		Net Carrying Amount
March 30, 2018
Definite-lived:
Purchased technology and patents	$	256,719	$	(121,802	)	$	3,432	$	138,349
Customer lists	759,987		(95,149		)	20,872		685,710
Other	4,534		(7,809		)	3,326		51
Total	$	1,021,240	$	(224,760	)	$	27,630	$	824,110
Indefinite-lived:
Trademarks and tradenames								$	90,288

December 29, 2017
Definite-lived:
Purchased technology and patents	$	256,719	$	(117,695	)	$	2,483	$	141,507
Customer lists	759,987		(87,555		)	16,103		688,535
Other	4,534		(7,797		)	3,326		63
Total	$	1,021,240	$	(213,047	)	$	21,912	$	830,105
Indefinite-lived:
Trademarks and tradenames								$	90,288

Schedule of Indefinite-Lived Intangible Assets

Intangible assets at March 30, 2018 and December 29, 2017 were as follows (in thousands):



	Gross Carrying Amount		Accumulated Amortization			Foreign Currency Translation		Net Carrying Amount
March 30, 2018
Definite-lived:
Purchased technology and patents	$	256,719	$	(121,802	)	$	3,432	$	138,349
Customer lists	759,987		(95,149		)	20,872		685,710
Other	4,534		(7,809		)	3,326		51
Total	$	1,021,240	$	(224,760	)	$	27,630	$	824,110
Indefinite-lived:
Trademarks and tradenames								$	90,288

December 29, 2017
Definite-lived:
Purchased technology and patents	$	256,719	$	(117,695	)	$	2,483	$	141,507
Customer lists	759,987		(87,555		)	16,103		688,535
Other	4,534		(7,797		)	3,326		63
Total	$	1,021,240	$	(213,047	)	$	21,912	$	830,105
Indefinite-lived:
Trademarks and tradenames								$	90,288

Schedule of Finite-Lived Intangible Assets, Amortization Expense

Aggregate intangible asset amortization expense is comprised of the following (in thousands):



	Three Months Ended
	March 30, 2018		March 31, 2017
Cost of sales	$	4,068	$	4,084
Selling, general and administrative expenses	7,606		6,758
Research, development and engineering costs	39		136
Total intangible asset amortization expense	$	11,713	$	10,978

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

Estimated future intangible asset amortization expense based on the carrying value as of March 30, 2018 is as follows (in thousands):



	2018		2019		2020		2021		2022		After 2022
Amortization Expense	$	33,872	$	45,724	$	46,349	$	45,470	$	43,430	$	609,265

Debt (Tables)

3 Months Ended

Mar. 30, 2018

Debt Disclosure [Abstract]

Schedule of Long-Term Debt

Long-term debt is comprised of the following (in thousands):



	March 30, 2018			December 29, 2017
Senior secured term loan A	$	328,125		$	335,157
Senior secured term loan B	830,286			873,286
9.125% senior notes due 2023	360,000			360,000
Revolving line of credit	74,000			74,000
Unamortized discount on term loan B and debt issuance costs	(30,654		)	(33,278		)
Total debt	1,561,757			1,609,165
Current portion of long-term debt	(32,813		)	(30,469		)
Total long-term debt	$	1,528,944		$	1,578,696

Schedule of Maturities of Long-term Debt

Contractual maturities under the Senior Secured Credit Facilities and Senior Notes for the remainder of 2018 and the next four years and thereafter, excluding any discounts or premiums, as of March 30, 2018 are as follows (in thousands):



	2018		2019		2020		2021		2022		After 2022
Future minimum principal payments	$	23,437	$	37,500	$	111,500	$	229,688	$	830,286	$	360,000

Schedule of Deferred Financing Fees

The change in deferred debt issuance costs related to the Revolving Credit Facility is as follows (in thousands):



December 29, 2017	$	2,808
Amortization during the period	(247		)
March 30, 2018	$	2,561

(4.) DEBT (Continued)

The change in unamortized discount and debt issuance costs related to the Term Loan Facilities and Senior Notes is as follows (in thousands):



	Debt Issuance Costs			Unamortized Discount on TLB Facility			Total
December 29, 2017	$	26,889		$	6,389		$	33,278
Write-off of debt issuance costs and unamortized discount⁽¹⁾	(745		)	(312		)	(1,057		)
Amortization during the period	(1,279		)	(288		)	(1,567		)
March 30, 2018	$	24,865		$	5,789		$	30,654

⁽¹⁾

The Company prepaid portions of its TLB Facility during 2018 and 2017. The Company recognized losses from extinguishment of debt during the quarters ended March 30, 2018 and March 31, 2017 of $1.1 million and $1.6 million, respectively, which is included in Interest Expense in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income. The loss from extinguishment of debt represents the portion of the unamortized discount and debt issuance costs related to the portion of the TLB Facility that was prepaid.

Schedule of Interest Rate Derivatives

Information regarding the Company’s outstanding interest rate swap designated as a cash flow hedge as of March 30, 2018 is as follows (dollars in thousands):



Notional Amount		Start Date	End Date	Pay Fixed Rate		Receive Current Floating Rate		Fair Value		Balance Sheet Location
$	200,000	Jun-17	Jun-20	1.1325	%	1.8750	%	$	5,544	Other Long-Term Assets

Benefit Plans (Tables)

3 Months Ended

Mar. 30, 2018

Defined Benefit Plan [Abstract]

Schedule of Net Defined Benefit Cost

Components of net defined benefit cost for these plans were comprised of the following (in thousands):



	Three Months Ended
	March 30, 2018			March 31, 2017
Service cost	$	127		$	110
Interest cost	46			38
Amortization of net loss	16			17
Expected return on plan assets	(4		)	(4		)
Net defined benefit cost	$	185		$	161

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

The components and classification of stock-based compensation expense were as follows (in thousands):



	Three Months Ended
	March 30, 2018		March 31, 2017
Stock options	$	331	$	710
RSAs and RSUs (time-based)	2,078		2,204
Performance-based RSUs (“PSUs”)	813		1,755
Total stock-based compensation expense	$	3,222	$	4,669

Cost of sales	$	220	$	142
Selling, general and administrative expenses	2,965		2,159
Research, development and engineering costs	33		105
Other operating expenses	4		2,263
Total stock-based compensation expense	$	3,222	$	4,669

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

The weighted average fair value and assumptions used to value options granted are as follows:



	Three Months Ended
	March 30, 2018			March 31, 2017
Weighted average fair value	$	14.89		$	9.14
Risk-free interest rate	2.21		%	1.63		%
Expected volatility	39		%	38		%
Expected life (in years)	4.0			3.7
Expected dividend yield	—		%	—		%

Schedule of Share-based Compensation, Stock Options Activity

The following table summarizes the Company’s stock option activity:



	Number of Stock Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (In Years)	Aggregate Intrinsic Value (In Millions)
Outstanding at December 29, 2017	931,353		$	30.89
Granted	28,447		45.13
Exercised	(27,322	)	36.81
Forfeited or expired	(818	)	48.43
Outstanding at March 30, 2018	931,660		$	31.14	5.7	$	23.7
Exercisable at March 30, 2018	777,521		$	30.03	5.0	$	20.6

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

The following table summarizes RSA and RSU activity:



	Time-Vested Activity		Weighted Average Fair Value
Nonvested at December 29, 2017	163,431		$	35.96
Granted	147,878		49.30
Vested	(11,999	)	49.78
Forfeited	(4,453	)	43.62
Nonvested at March 30, 2018	294,857		$	41.97

The following table summarizes PSU activity:



	Performance- Vested Activity		Weighted Average Fair Value
Nonvested at December 29, 2017	469,889		$	32.37
Granted	159,669		45.37
Vested	(127,191	)	34.29
Forfeited	(129,311	)	33.36
Nonvested at March 30, 2018	373,056		$	36.93

Other Operating Expenses, Net (Tables)

3 Months Ended

Mar. 30, 2018

Other Income and Expenses [Abstract]

Schedule of Other Operating Cost and Expense By Component

Other Operating Expenses is comprised of the following (in thousands):



	Three Months Ended
	March 30, 2018		March 31, 2017
Strategic reorganization and alignment	$	3,492	$	—
Manufacturing alignment to support growth	513		—
Consolidation and optimization initiatives	605		2,395
Acquisition and integration expenses	—		4,820
Asset dispositions, severance and other	667		4,556
Total other operating expenses	$	5,277	$	11,771

Schedule of Changes in Accrued Liabilities

The following table summarizes the change in accrued liabilities related to the initiatives described above (in thousands):



	Severance and Retention			Other			Total
December 29, 2017	$	1,308		$	—		$	1,308
Restructuring charges	3,274			1,336			4,610
Cash payments	(3,136		)	(897		)	(4,033		)
March 30, 2018	$	1,446		$	439		$	1,885

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Product Warranty Liability

The change in product warranty liability was comprised of the following (in thousands):



December 29, 2017	$	4,745
Additions to warranty reserve	256
Warranty claims settled	(69		)
March 30, 2018	$	4,932

Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance

The impact to the Company’s results of operations from its forward contract hedges is as follows (in thousands):



	Three Months Ended
	March 30, 2018			March 31, 2017
Increase in sales	$	139		$	24
Increase (decrease) in cost of sales	(436		)	1,062
Ineffective portion of change in fair value	—			—

Schedule of Foreign Exchange Contracts, Statement of Financial Position

Information regarding outstanding foreign currency contracts designated as cash flow hedges as of March 30, 2018 is as follows (dollars in thousands):

Aggregate

Notional

Amount

Start

Date

End

Date

$/Foreign Currency

Fair

Value

Balance Sheet Location

$

2,313

Jan 2018

Jun 2018

0.0514

Peso

$

142

Prepaid expenses and other current assets

22,798

Jan 2018

Dec 2018

0.0507

Peso

1,403

Prepaid expenses and other current assets

21,900

Jan 2018

Dec 2018

1.2089

Euro

644

Prepaid expenses and other current assets

Earnings (Loss) Per Share (EPS) (Tables)

3 Months Ended

Mar. 30, 2018

Earnings Per Share [Abstract]

Schedule of Calculation of Numerator and Denominator in Earnings Per Share

The following table illustrates the calculation of basic and diluted EPS (in thousands, except per share amounts):



	Three Months Ended
	March 30, 2018		March 31, 2017
Numerator for basic and diluted EPS:
Net income (loss)	$	8,118	$	(4,339	)
Denominator for basic EPS:
Weighted average shares outstanding	31,902		31,016
Effect of dilutive securities:
Stock options, restricted stock and RSUs	521		—
Denominator for diluted EPS	32,423		31,016
Basic EPS	$	0.25	$	(0.14	)
Diluted EPS	$	0.25	$	(0.14	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands):



	Three Months Ended
	March 30, 2018	March 31, 2017
Time-vested stock options, restricted stock and RSUs	150	1,700
Performance-vested restricted stock and PSUs	182	593

Accumulated Other Comprehensive Income (Loss) (Tables)

3 Months Ended

Mar. 30, 2018

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Accumulated Other Comprehensive Income is comprised of the following (in thousands):



	Defined Benefit Plan Liability			Cash Flow Hedges			Foreign Currency Translation Adjustment		Total Pre-Tax Amount			Tax			Net-of-Tax Amount
December 29, 2017	$	(1,422	)	$	3,418		$	50,200	$	52,196		$	(17	)	$	52,179
Unrealized gain on cash flow hedges	—			5,124			—		5,124			(1,076		)	4,048
Realized gain on foreign currency hedges	—			(575		)	—		(575		)	121			(454		)
Realized gain on interest rate swap hedges	—			(234		)	—		(234		)	49			(185		)
Foreign currency translation gain	—			—			13,441		13,441			—			13,441
March 30, 2018	$	(1,422	)	$	7,733		$	63,641	$	69,952		$	(923	)	$	69,029



December 30, 2016	$	(1,475	)	$	1,420		$	(15,660	)	$	(15,715	)	$	(285	)	$	(16,000	)
Unrealized gain on cash flow hedges	—			1,712			—			1,712			(599		)	1,113
Realized loss on foreign currency hedges	—			1,086			—			1,086			(380		)	706
Realized gain on interest rate swap hedges	—			(106		)	—			(106		)	37			(69		)
Foreign currency translation gain	—			—			6,536			6,536			—			6,536
March 31, 2017	$	(1,475	)	$	4,112		$	(9,124	)	$	(6,487	)	$	(1,227	)	$	(7,714	)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 30, 2018

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):



	Fair Value		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
March 30, 2018
Assets: Foreign currency contracts (Note 9)	$	2,189	$	—	$	2,189	$	—
Assets: Interest rate swap (Note 4)	5,544		—		5,544		—

December 29, 2017
Assets: Interest rate swaps	$	4,279	$	—	$	4,279	$	—
Liabilities: Foreign currency contracts	861		—		861		—

Segment Information (Tables)

3 Months Ended

Mar. 30, 2018

Segment Reconciliation [Abstract]

Reconciliation of Revenue from Segments to Consolidated



	Three Months Ended
	March 30, 2018		March 31, 2017
Segment sales by product line:
Medical
Cardio & Vascular	$	138,348	$	125,108
Cardiac & Neuromodulation	108,910		103,813
Advanced Surgical, Orthopedics & Portable Medical	121,775		105,146
Total Medical	369,033		334,067
Non-Medical	12,712		11,346
Total sales	$	381,745	$	345,413

Reconciliation of Operating Profit (Loss) from Segments to Consolidated



	Three Months Ended
	March 30, 2018			March 31, 2017
Segment income from operations:
Medical	$	52,127		$	50,360
Non-Medical	3,198			1,562
Total segment income from operations	55,325			51,922
Unallocated operating expenses	(20,608		)	(25,377		)
Operating income	34,717			26,545
Unallocated expenses, net	(22,508		)	(30,740		)
Income (loss) before income taxes	$	12,209		$	(4,195	)

Revenue From Contracts With Customers (Tables)

3 Months Ended

Mar. 30, 2018

Revenue from Contract with Customer [Abstract]

Summary of Disaggregation of Revenue

The following table presents revenues by customer for the three months ended March 30, 2018.



Customer	Medical		Non-Medical
Customer A	17	%	—	%
Customer B	16	%	—	%
Customer C	15	%	—	%
Customer D	—	%	19	%
Customer E	—	%	11	%
All other customers	52	%	70	%

The following table presents revenues by ship to country for the three months ended March 30, 2018.



Ship to Location	Medical		Non-Medical
United States	55	%	69	%
Puerto Rico	10	%	—	%
Canada	—	%	11	%
All other Countries	35	%	20	%

Impact of Recently Issued Accounting Standards (Tables)

3 Months Ended

Mar. 30, 2018

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Summary of Recently Issued Accounting Standards

The following table provides a brief description of recent Accounting Standard Updates ("ASU") issued by the Financial Accounting Standards Board ("FASB"):



Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.	The new guidance allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and will improve the usefulness of information reported to financial statement users.	December 29, 2018 (beginning of 2019 fiscal year). Early adoption is permitted.	The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements.
In August 2017, the FASB issued ASU 2017-12, Targeted Improvements to Accounting for Hedging Activities.	The new guidance improves the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results.	December 29, 2018. Early adoption is permitted.	The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements.
In March 2017, the FASB issued ASU 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.	The new guidance clarifies the presentation and classification of the components of net periodic benefit costs in the consolidated statement of operations.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017, the beginning of its 2018 fiscal year, using the retrospective transition method, as part of the FASB's simplification initiative. See Adoption of ASU 2017-07 section below for additional information.
In October 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory.	The new guidance requires the income tax consequences of an intra-entity transfer of assets other than inventory to be recognized when the transfer occurs rather than deferring until an outside sale has occurred.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.
In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments.	The new guidance clarifies the presentation and classification of certain cash receipts and cash payments in the statement of cash flows.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.
In February 2016, the FASB issued ASU 2016-02, Leases.	The new guidance supersedes the lease guidance under ASC Topic 840, Leases, resulting in the creation of FASB ASC Topic 842, Leases. The guidance requires a lessee to recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term for both finance and operating leases.	December 29, 2018. Early adoption is permitted.	The Company is currently evaluating its population of leases, and is continuing to assess all potential impacts of the standard, but currently believes the most significant impact relates to its accounting for real estate operating leases. The Company anticipates recognition of additional assets and corresponding liabilities related to leases upon adoption, but has not yet quantified these at this time. The Company plans to adopt the standard effective December 29, 2018.

(15.) IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS (Continued)



Standard	Description	Effective Date	Effect on the Financial Statements or Other Significant Matters
In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities.	The new guidance updates certain aspects of recognition, measurement, presentation and disclosure of financial instruments.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017. The adoption of the new guidance did not have a material impact to the Company.
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. Since that date, the FASB has issued additional ASUs clarifying certain aspects of ASU 2014-09.	The new guidance requires entities to recognize revenue in a way that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The new guidance provides alternative methods of adoption. Subsequent guidance issued after May 2014 did not change the core principle of ASU 2014-09.	December 30, 2017.	The Company adopted the new guidance effective December 30, 2017, using the modified retrospective transition method applied to those contracts which were not completed as of December 30, 2017. Prior period amounts have not been adjusted and continue to be reflected in accordance with the Company’s historical accounting. The adoption of this ASU did not have a material impact on the consolidated financial statements and therefore no cumulative adjustment was recorded to equity. The Company has updated its internal controls for changes and expanded disclosures have been made in the Notes to the Financial Statements as a result of adopting the standard. (See Note 14, “Revenue from Contracts with Customers”).

Basis of Presentation (Narrative) (Details)	3 Months Ended
Basis of Presentation (Narrative) (Details)	Mar. 30, 2018	Mar. 31, 2017
Accounting Policies [Abstract]
Fiscal Period Duration	91 days	91 days

Inventories (Details) - USD ($) $ in Thousands	Mar. 30, 2018	Dec. 29, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 96,405	$ 97,615
Work-in-process	104,612	92,650
Finished goods	38,473	37,269
Total	$ 239,490	$ 227,534

Goodwill and Other Intangible Assets, Net (Schedule of Indefinite-Lived Intangible Assets and Goodwill) (Details) $ in Thousands	3 Months Ended
	Mar. 30, 2018 USD ($)
Goodwill [Roll Forward]
Goodwill	$ 990,238
Foreign currency translation	4,962
Goodwill	995,200
Medical Segment [Member]
Goodwill [Roll Forward]
Goodwill	973,238
Foreign currency translation	4,962
Goodwill	978,200
Non-Medical Segment [Member]
Goodwill [Roll Forward]
Goodwill	17,000
Foreign currency translation	0
Goodwill	$ 17,000

Goodwill and Other Intangible Assets, Net (Schedule of Finite-Lived Intangible Assets, Major Class) (Details) - USD ($) $ in Thousands	Mar. 30, 2018	Dec. 29, 2017
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,021,240	$ 1,021,240
Accumulated Amortization	(224,760)	(213,047)
Foreign Currency Translation	27,630	21,912
Total estimated amortization expense	824,110	830,105
Trademarks And Tradenames [Member]
Finite-Lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	90,288	90,288
Purchased Technology And Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	256,719	256,719
Accumulated Amortization	(121,802)	(117,695)
Foreign Currency Translation	3,432	2,483
Total estimated amortization expense	138,349	141,507
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	759,987	759,987
Accumulated Amortization	(95,149)	(87,555)
Foreign Currency Translation	20,872	16,103
Total estimated amortization expense	685,710	688,535
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,534	4,534
Accumulated Amortization	(7,809)	(7,797)
Foreign Currency Translation	3,326	3,326
Total estimated amortization expense	$ 51	$ 63

Goodwill and Other Intangible Assets, Net (Schedule of Finite-Lived Intangible Assets, Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	$ 11,713	$ 10,978
Cost of Sales [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	4,068	4,084
Selling General And Administrative Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	7,606	6,758
Research and Development Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	$ 39	$ 136

Goodwill and Other Intangible Assets, Net (Schedule of Finite-Lived Intangible Assets, Future Amortization Expense) (Details) $ in Thousands	Mar. 30, 2018 USD ($)
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2018	$ 33,872
2019	45,724
2020	46,349
2021	45,470
2022	43,430
After 2022	$ 609,265

Debt (Schedule of Long-Term Debt) (Details) - USD ($) $ in Thousands	Mar. 30, 2018	Dec. 29, 2017	Oct. 27, 2015
Debt Instrument [Line Items]
Unamortized discount on term loan B and debt issuance costs	$ (30,654)	$ (33,278)
Total debt	1,561,757	1,609,165
Current portion of long-term debt	(32,813)	(30,469)
Total long-term debt	$ 1,528,944	1,578,696
Senior Notes [Member] \| 9.125% Senior Notes due 2023 [Member]
Debt Instrument [Line Items]
Stated interest rate	9.125%		9.125%
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 328,125	335,157
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan B (TLB) Facility [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	830,286	873,286
Secured Debt [Member] \| Loans Payable [Member] \| 9.125% Senior Notes due 2023 [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	360,000	360,000
Secured Debt [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 74,000	$ 74,000

Debt (Credit Facility) (Details)		3 Months Ended
Debt (Credit Facility) (Details)	Oct. 27, 2015 USD ($) loan_facility	Mar. 30, 2018 USD ($)
Senior Notes [Member] \| 9.125% Senior Notes due 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 360,000,000
Debt Instrument, Maturity Date	Nov. 01, 2023
Long-term Debt, Fair Value		$ 390,000,000
Stated interest rate	9.125%	9.125%
Secured Debt [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity	$ 200,000,000
Debt Instrument, Maturity Date	Oct. 27, 2020
Revolving line of credit		$ 74,000,000
Line of Credit Facility, Remaining Borrowing Capacity		116,800,000
Letters of Credit Outstanding, Amount		$ 9,200,000
Debt Weighted Average Interest Rate		5.10%
Secured Debt [Member] \| Loans Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Compliance, Number Of Additional Term Loan Facilities That May Be Added \| loan_facility	1
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 375,000,000
Debt Instrument, Maturity Date	Oct. 27, 2021
Debt Weighted Average Interest Rate		5.13%
Debt Instrument, Covenant Compliance, Maximum Leverage Ratio	6.0
Debt Instrument, Covenant Compliance, Adjusted EBITDA To Interest Expense Ratio	2.75
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan B (TLB) Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 1,025,000,000
Debt Instrument, Discount, Percentage	1.00%
Reduction to the variable rate basis spread		0.25%
Debt Instrument, Maturity Date	Oct. 27, 2022
Debt Weighted Average Interest Rate		4.99%
Long-term Debt, Fair Value		$ 839,000,000
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan B (TLB) Facility [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Variable rate basis spread	2.25%
Secured Debt [Member] \| Loans Payable [Member] \| Term Loan B (TLB) Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Variable rate basis spread	3.25%
Debt Instrument, Interest Rate, Floor	1.00%
Secured Debt [Member] \| Swingline Loans [Member] \| New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity	$ 15,000,000
Secured Debt [Member] \| Standby Letters of Credit [Member] \| New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity	$ 25,000,000
Secured Debt [Member] \| Minimum [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.175%
Secured Debt [Member] \| Minimum [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Variable rate basis spread	0.75%
Secured Debt [Member] \| Minimum [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Variable rate basis spread	1.75%
Secured Debt [Member] \| Minimum [Member] \| Loans Payable [Member] \| Term Loan A (TLA) Facility [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Variable rate basis spread	0.75%
Secured Debt [Member] \| Minimum [Member] \| Loans Payable [Member] \| Term Loan A (TLA) Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Variable rate basis spread	1.75%
Secured Debt [Member] \| Maximum [Member] \| Senior Secured Credit Facilities [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Compliance, First Lien Net Leverage Ratio	4.25
Secured Debt [Member] \| Maximum [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Secured Debt [Member] \| Maximum [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Variable rate basis spread	2.25%
Secured Debt [Member] \| Maximum [Member] \| Revolving Credit Facility [Member] \| New Revolving Credit Facility 2015 [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Variable rate basis spread	3.25%
Secured Debt [Member] \| Maximum [Member] \| Loans Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Compliance, First Lien Net Leverage Ratio	4.25
Secured Debt [Member] \| Maximum [Member] \| Loans Payable [Member] \| Term Loan A (TLA) Facility [Member] \| Prime Rate [Member]
Debt Instrument [Line Items]
Variable rate basis spread	2.25%
Secured Debt [Member] \| Maximum [Member] \| Loans Payable [Member] \| Term Loan A (TLA) Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Variable rate basis spread	3.25%

Debt (Long-term Debt Maturity Schedule) (Details) $ in Thousands	Mar. 30, 2018 USD ($)
Debt Disclosure [Abstract]
2018	$ 23,437
2019	37,500
2020	111,500
2021	229,688
2022	830,286
After 2022	$ 360,000

Debt (Schedule of Deferred Financing Fees) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Deferred Finance Costs [Roll Forward]
Total, Beginning Balance	$ 33,278
Amortization during the period	(2,871)	$ (3,437)
Total, Ending Balance	30,654
Loss on extinguishment of debt	1,100	$ 1,600
Revolving Credit Facility [Member]
Deferred Finance Costs [Roll Forward]
Deferred Finance Costs, Net, Beginning Balance	2,808
Amortization during the period	(247)
Deferred Finance Costs, Net, Ending Balance	2,561
Term Loan And Senior Notes [Member]
Deferred Finance Costs [Roll Forward]
Deferred Finance Costs, Net, Beginning Balance	26,889
Write-off of debt issuance costs and unamortized discount	(745)
Amortization during the period	(1,279)
Deferred Finance Costs, Net, Ending Balance	24,865
Total, Beginning Balance	33,278
Write-off of debt issuance costs and unamortized discount	(1,057)
Amortization during the period	(1,567)
Total, Ending Balance	30,654
Term Loan B (TLB) Facility [Member]
Deferred Finance Costs [Roll Forward]
Unamortized Discount on TLB Facility, Beginning Balance	6,389
Write-off of debt issuance costs and unamortized discount	(312)
Amortization during the period	(288)
Unamortized Discount on TLB Facility, Ending Balance	$ 5,789

Debt (Schedule of Interest Rate Swaps and Details) (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jun. 30, 2016	Mar. 30, 2018	Mar. 31, 2017
Interest Rate Swap 3 [Member]
Derivative [Line Items]
Derivative, Term of Contract	3 years
Derivative Liability, Notional Amount	$ 200,000,000
Notional Amount		$ 200,000,000
Pay Fixed Rate		1.1325%
Receive Current Floating Rate		1.875%
Fair Value, Asset		$ 5,544,000
Interest Rate Swap [Member]
Derivative [Line Items]
Gain (Loss) Recognized In Income Ineffective Portion		0	$ 0
Reduction (Increase) to Interest Expense		200,000	$ (100,000)
Gain expected to be reclassified into earnings within the next twelve months		$ 2,000,000

Benefit Plans (Schedule of Net Defined Benefit Cost) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Defined Benefit Plan [Abstract]
Service cost	$ 127	$ 110
Interest cost	46	38
Amortization of net loss	16	17
Expected return on plan assets	(4)	(4)
Net defined benefit cost	$ 185	$ 161

Stock-Based Compensation (Allocation of Recognized Period Costs) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 3,222	$ 4,669
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	220	142
Selling General And Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	2,965	2,159
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	33	105
Other Operating Income (Expense) [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	4	2,263
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	331	710
RSAs and RSUs (time-based) [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	2,078	2,204
Performance-based RSUs (PSUs) [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 813	$ 1,755

Stock-Based Compensation (Valuation Assumptions) (Details) - $ / shares	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value	$ 14.89	$ 9.14
Risk-free interest rate	2.21%	1.63%
Expected volatility	39.00%	38.00%
Expected life (in years)	4 years	3 years 8 months
Expected dividend yield	0.00%	0.00%

Stock-Based Compensation (Stock Options Activity) (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 30, 2018 USD ($) $ / shares shares
Stock Option Activity (in shares)
Options Outstanding, Beginning \| shares	931,353
Granted \| shares	28,447
Exercised \| shares	(27,322)
Forfeited or expired \| shares	(818)
Options Outstanding, Ending \| shares	931,660
Options Exercisable \| shares	777,521
Weighted Average Exercise Price (in dollars per share)
Options Outstanding, Beginning \| $ / shares	$ 30.89
Granted \| $ / shares	45.13
Exercised \| $ / shares	36.81
Forfeited or expired \| $ / shares	48.43
Options Outstanding, Ending \| $ / shares	31.14
Options Exercisable \| $ / shares	$ 30.03
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options Outstanding, Weighted Average Remaining Contractual Term	5 years 8 months
Options Exercisable, Weighted Average Remaining Contractual Term	5 years
Options Outstanding, Intrinsic Value \| $	$ 23.7
Options Exercisable, Intrinsic Value \| $	$ 20.6

Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details)	3 Months Ended
	Mar. 30, 2018 $ / shares shares
Restricted Stock And Restricted Stock Units Time Based [Member]
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, Beginning \| shares	163,431
Granted \| shares	147,878
Vested \| shares	(11,999)
Forfeited \| shares	(4,453)
Nonvested, Ending \| shares	294,857
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, Beginning \| $ / shares	$ 35.96
Granted \| $ / shares	49.30
Vested \| $ / shares	49.78
Forfeited \| $ / shares	43.62
Nonvested, Ending \| $ / shares	$ 41.97
Performance-based RSUs (PSUs) [Member]
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, Beginning \| shares	469,889
Granted \| shares	159,669
Vested \| shares	(127,191)
Forfeited \| shares	(129,311)
Nonvested, Ending \| shares	373,056
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, Beginning \| $ / shares	$ 32.37
Granted \| $ / shares	45.37
Vested \| $ / shares	34.29
Forfeited \| $ / shares	33.36
Nonvested, Ending \| $ / shares	$ 36.93

Stock-Based Compensation (Additional Information) (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Acceleration of remaining compensation expense		$ 2.2
Performance period	3 years
Expected life (in years)	4 years	3 years 8 months
Risk-free interest rate	2.21%	1.63%
Expected dividend yield	0.00%	0.00%
Expected volatility	39.00%	38.00%
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted	0.3
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted	0.2
Performance Shares [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Performance Shares [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Financial Performance Stock Units [Member] \| Performance Period Ending January 1, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted	0.1
TSR Performance Stock Units [Member] \| Performance Period Ending January 1, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted	0.1
Time-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance-based RSUs (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	2 years 11 months
Risk-free interest rate	2.28%
Expected dividend yield	0.00%
Expected volatility	40.00%

Other Operating Expenses, Net (Schedule of Other Operating Cost and Expense By Component) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	$ 5,277	$ 11,771
Strategic Reorganization And Alignment [Member]
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	3,492	0
Manufacturing Alignment To Support Growth [Member]
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	513	0
Consolidation And Optimization Initiatives [Member]
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	605	2,395
Acquisition and Integration Expenses [Member]
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	0	4,820
Asset Dispositions, Severance And Other [Member]
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	$ 667	$ 4,556

Other Operating Expenses, Net (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 29, 2017	Mar. 30, 2018
Strategic Reorganization And Alignment [Member]
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception			$ 9.4
Strategic Reorganization And Alignment [Member] \| Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Expected costs		$ 10.0
Expected cash outlays		8.0
Strategic Reorganization And Alignment [Member] \| Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Expected costs		12.0
Expected cash outlays		12.0
Manufacturing Alignment To Support Growth [Member]
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception			$ 0.9
Manufacturing Alignment To Support Growth [Member] \| Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Expected costs		9.0
Expected capital expenditures		4.0
Manufacturing Alignment To Support Growth [Member] \| Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Expected costs		11.0
Expected capital expenditures		6.0
Acquisition And Integration Costs [Member] \| Lake Region Medical [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition related transaction costs	$ 4.8
Acquisition and integration costs accrued		0.4
Asset Dispositions, Severance And Other [Member]
Restructuring Cost and Reserve [Line Items]
Leadership transition costs		$ 4.7

Other Operating Expenses, Net (Schedule of Restructuring Reserve By Type of Cost) (Details) - Consolidation And Optimization Initiatives [Member] $ in Thousands	3 Months Ended
	Mar. 30, 2018 USD ($)
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	$ 1,308
Restructuring charges	4,610
Cash payments	(4,033)
Restructuring Reserve, Ending Balance	1,885
Severance And Retention [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	1,308
Restructuring charges	3,274
Cash payments	(3,136)
Restructuring Reserve, Ending Balance	1,446
Other Restructuring [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	1,336
Cash payments	(897)
Restructuring Reserve, Ending Balance	$ 439

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Mar. 30, 2018	Mar. 31, 2017	Dec. 29, 2017
Income Tax Disclosure [Abstract]
Unrecognized foreign earnings and profits			$ 147,500
Provisional income tax expense			14,700
Tax benefit from revaluation of net deferred tax liabilities			$ 56,500
Effective income tax rate	33.50%	(3.40%)
Income (loss) before provision for income taxes	$ 12,209	$ (4,195)
Federal statutory tax rate	21.00%		35.00%
Unrecognized Tax Benefits	$ 12,700
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	1,100
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 12,300

Commitments and Contingencies (Narrative) (Details)		3 Months Ended
Commitments and Contingencies (Narrative) (Details)	Jan. 26, 2016 USD ($) patent	Mar. 30, 2018 USD ($)
Gain Contingencies [Line Items]
Gain (Loss) Related to Litigation Settlement		$ 0
Product Warranty Description		The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship.
Positive Outcome of Litigation [Member]
Gain Contingencies [Line Items]
Gain Contingency, Patents Found Infringed upon, Number \| patent	2
Amount awarded from other party	$ 37,500,000

Commitments and Contingencies (Schedule of Product Warranty Liability) (Details) $ in Thousands	3 Months Ended
	Mar. 30, 2018 USD ($)
Movement in Standard Product Warranty Accrual [Roll Forward]
December 29, 2017	$ 4,745
Additions to warranty reserve	256
Warranty claims settled	(69)
March 30, 2018	$ 4,932

Commitments and Contingencies (Foreign Currency Contracts) (Details) $ in Thousands	3 Months Ended
	Mar. 30, 2018 USD ($)	Mar. 31, 2017 USD ($)
Foreign Currency Cash Flow Hedges [Abstract]
Increase in sales	$ 139	$ 24
Increase (decrease) in cost of sales	(436)	1,062
Ineffective portion of change in fair value	0	$ 0
Foreign Currency Cash Flow Hedge [Line Items]
Foreign currency cash flow hedge gain (loss) to be reclassified	2,200
FX Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Aggregate Notional Amount	$ 2,313
Start Date	Jan. 01, 2018
End Date	Jun. 29, 2018
FX Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Aggregate Notional Amount	$ 22,798
Start Date	Jan. 01, 2018
End Date	Dec. 28, 2018
FX Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Aggregate Notional Amount	$ 21,900
Start Date	Jan. 01, 2018
End Date	Dec. 28, 2018
Accrued Expenses [Member] \| FX Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Foreign Currency Cash Flow Hedge Asset at Fair Value	$ 142
Accrued Expenses [Member] \| FX Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Foreign Currency Cash Flow Hedge Asset at Fair Value	1,403
Accrued Expenses [Member] \| FX Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Foreign Currency Cash Flow Hedge Asset at Fair Value	$ 644
Peso [Member] \| FX Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
$/Foreign Currency	0.0514
Peso [Member] \| FX Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
$/Foreign Currency	0.0507
Euro [Member] \| FX Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
$/Foreign Currency	1.2089

Earnings (Loss) Per Share (EPS) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Net income (loss)	$ 8,118	$ (4,339)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Basic (in shares)	31,902,000	31,016,000
Stock options, restricted stock and restricted stock units (in shares)	521,000	0
Denominator for diluted EPS (in shares)	32,423,000	31,016,000
Basic EPS (in dollars per share)	$ 0.25	$ (0.14)
Diluted EPS (in dollars per share)	$ 0.25	$ (0.14)
Anitdilutive Securities Excluded From Earnings Per Share [Abstract]
Time-vested stock options, restricted stock and restricted stock units (in shares)	150,000	1,700,000
Performance-vested stock options and restricted stock units (in shares)	182,000	593,000

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Defined Benefit Plan Liability
Defined Benefit Plan Liability, Beginning	$ (1,422)	$ (1,475)
Defined Benefit Plan Liability, Ending	(1,422)	(1,475)
Cash Flow Hedges
Cash Flow Hedges, Beginning	3,418	1,420
Unrealized loss on cash flow hedges	5,124	1,712
Realized gain loss on foreign currency hedges - before tax	(575)	1,086
Realized gain loss on interest rate swaps - before tax	(234)	(106)
Cash Flow Hedges, End	7,733	4,112
Foreign Currency Translation Adjustment
Foreign Currency Translation Adjustment, Beginning	50,200	(15,660)
Net foreign currency translation gain (loss)	13,441	6,536
Foreign Currency Translation Adjustment, End	63,641	(9,124)
Total Pre-Tax Amount
Total Pre-Tax Amount, Beginning	52,196	(15,715)
Unrealized loss on cash flow hedges	5,124	1,712
Realized gain loss on foreign currency hedges - before tax	(575)	1,086
Realized gain loss on interest rate swaps - before tax	(234)	(106)
Net foreign currency translation gain (loss)	13,441	6,536
Total Pre-Tax Amount, End	69,952	(6,487)
Tax
Tax, Beginning	(17)	(285)
Unrealized gain (loss) on cash flow hedges	(1,076)	(599)
Realized gain loss on foreign currency contracts - tax	121	(380)
Realized gain loss on interest rate swap hedges - tax	49	37
Net foreign currency translation gain (loss)	0	0
Tax, End	(923)	(1,227)
Net-of-Tax Amount
Total Net-of-Tax Amount, Beginning	52,179	(16,000)
Unrealized gain (loss) on cash flow hedges, net of tax	4,048	1,113
Realized gain loss on foreign currency hedges, net of tax	(454)	706
Realized gain loss on interest rate swap hedges, net of tax	(185)	(69)
Foreign currency translation gain (loss)	13,441	6,536
Total Net-of-Tax Amount, End	$ 69,029	$ (7,714)

Fair Value Measurements (Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Mar. 30, 2018	Dec. 29, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts assets	$ 2,189
Foreign currency contracts liabilities		$ 861
Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap assets	5,544	4,279
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts assets	0
Foreign currency contracts liabilities		0
Fair Value, Inputs, Level 1 [Member] \| Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap assets	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts assets	2,189
Foreign currency contracts liabilities		861
Fair Value, Inputs, Level 2 [Member] \| Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap assets	5,544	4,279
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts assets	0
Foreign currency contracts liabilities		0
Fair Value, Inputs, Level 3 [Member] \| Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap assets	$ 0	$ 0

Fair Value Measurements (Narrative) (Details) - USD ($)	3 Months Ended
Fair Value Measurements (Narrative) (Details) - USD ($)	Mar. 30, 2018	Mar. 31, 2017	Dec. 29, 2017
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Cost method and equity method investments, carrying value	$ 25,800,000		$ 20,800,000
Cost method investment	7,000,000		7,000,000
Impairment on cost method investments	0	$ 0
Fair Value, Inputs, Level 2 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Gain (loss) on equity method investments	5,000,000	$ (400,000)
Chinese Venture Capital Fund [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Equity method investment	$ 18,800,000		$ 13,800,000
Equity method investment ownership (percent)	6.60%

Segment Information (Narrative) (Details)	3 Months Ended
Segment Information (Narrative) (Details)	Mar. 30, 2018 Segment
Segment Reporting [Abstract]
Number of Reportable Segments	2

Segment Information (Reconciliation of Revenue from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	$ 381,745	$ 345,413
Operating Segments [Member] \| Medical Segment [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	369,033	334,067
Operating Segments [Member] \| Medical Segment [Member] \| Cardio And Vascular [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	138,348	125,108
Operating Segments [Member] \| Medical Segment [Member] \| Cardiac Neuromodulation [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	108,910	103,813
Operating Segments [Member] \| Medical Segment [Member] \| Advanced Surgical, Orthopedics, and Portable Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	121,775	105,146
Operating Segments [Member] \| Non-Medical Segment [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	$ 12,712	$ 11,346

Segment Information (Reconciliation of Operating Profit (Loss) from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 30, 2018	Mar. 31, 2017
Segment Reporting Information [Line Items]
Operating income	$ 34,717	$ 26,545
Unallocated expenses, net	(22,508)	(30,740)
Income (loss) before income taxes	12,209	(4,195)
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income	55,325	51,922
Operating Segments [Member] \| Medical Segment [Member]
Segment Reporting Information [Line Items]
Operating income	52,127	50,360
Operating Segments [Member] \| Non-Medical Segment [Member]
Segment Reporting Information [Line Items]
Operating income	3,198	1,562
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Operating income	$ (20,608)	$ (25,377)

Revenue From Contracts With Customers (Disaggregated Revenue) (Details) - Revenue from Contract with Customer [Member]	3 Months Ended
	Mar. 30, 2018
Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer A [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	17.00%
Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer B [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	16.00%
Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer C [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	15.00%
Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer D [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer E [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Medical Segment [Member] \| Customer Concentration Risk [Member] \| All Other Customers [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	52.00%
Medical Segment [Member] \| Geographic Concentration Risk [Member] \| United States [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	55.00%
Medical Segment [Member] \| Geographic Concentration Risk [Member] \| Puerto Rico [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	10.00%
Medical Segment [Member] \| Geographic Concentration Risk [Member] \| Canada [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Medical Segment [Member] \| Geographic Concentration Risk [Member] \| All Other Countries [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	35.00%
Non-Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer A [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Non-Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer B [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Non-Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer C [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Non-Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer D [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	19.00%
Non-Medical Segment [Member] \| Customer Concentration Risk [Member] \| Customer E [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	11.00%
Non-Medical Segment [Member] \| Customer Concentration Risk [Member] \| All Other Customers [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	70.00%
Non-Medical Segment [Member] \| Geographic Concentration Risk [Member] \| United States [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	69.00%
Non-Medical Segment [Member] \| Geographic Concentration Risk [Member] \| Puerto Rico [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	0.00%
Non-Medical Segment [Member] \| Geographic Concentration Risk [Member] \| Canada [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	11.00%
Non-Medical Segment [Member] \| Geographic Concentration Risk [Member] \| All Other Countries [Member]
Disaggregation of Revenue [Line Items]
Concentration risk percentage	20.00%

Revenue From Contracts With Customers Revenue From Contracts With Customers (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 30, 2018	Dec. 29, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Contract liabilities	$ 4,400,000	$ 3,600,000
Revenue recognized that was included in contract liability balance at beginning of period	700,000
Contract assets	$ 0	$ 0
Minimum [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Payment terms	30 days
Maximum [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Payment terms	90 days

Subsequent Event (Narrative) (Details) $ in Millions	3 Months Ended
Subsequent Event (Narrative) (Details) $ in Millions	Sep. 28, 2018 USD ($)
Scenario, Forecast [Member] \| Advanced Surgical And Orthopedic Product Lines [Member] \| Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] \| Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from Divestiture of Businesses	$ 600